NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Zynex, Inc. (OTCMKTS: ZYXIQ) (“Zynex” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Zynex shares between February 25, 2021 and December 15, 2025, both dates inclusive (the "Class Period"). Investors have until April 21, 2026, to seek appointments as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUB ...

Core Insights - Blackstone Secured Lending (BXSL) has demonstrated consistent asset quality and strong net investment income (NII) coverage, making it valuable to Business Development Company (BDC) investors [1] Group 1 - BXSL has shown resilience over time despite facing downward market pressures [1]

Meta quietly tried to block attorneys from asking Mark Zuckerberg about his massive fortune at the bombshell social media addiction trial in Los Angeles, according to court documents reviewed by The Post.The owner of Instagram and Facebook made a confidential request to “shield Mark Zuckerberg, Meta’s founder, CEO, and controlling shareholder, from the very same scrutiny that other witnesses have faced,” according to a filing unsealed last Friday in Los Angeles County Superior Court.The plaintiffs allege th ...

Low-Cost Active ETFs Post Higher Success RatesLow-cost active ETFs succeeded at nearly double the rate of their expensive counterparts over the past decade, according to Morningstar's year-end 2025 Active/Passive Barometer [report], underscoring how fees remain the primary hurdle for active managers attempting to outpace index funds.The research found that 31% of active funds in the cheapest quintile of their categories beat their average passive peer over 10 years. This is compared with just 17% for the pr ...

PresentationGood day, and thank you for standing by. Welcome to the Rackspace Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sagar Hebbar, Head of Investor Relations. Please go ahead.Sagar HebbarHead of Investor Relations Thank you, and welcome to Rackspace Technologies Fourth Quarter 2025 Earnings Conference Call. I'm Sagar Hebbar, Head of Investor Relation ...

A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel on Sept. 9, 2025.Novartis, one of the world's largest pharmaceutical companies, and Genentech, a major biotech firm, say they've uncovered a "dangerous scheme" to import their allergy medication from Canada into the U.S. in violation of U.S. Food and Drug Administration regulations.Both are suing SHARx — a so-called alternative funding program — and a Canadian pharmacy over the importation of Xolair, a ...

It was a wild last few years for gold and for a fund I've covered twice before now , the WisdomTree Efficient Gold Plus Gold Miners ETF ( GDMN ). I'll get into the mechanics later, but essentially the fund is aWriter | Investment Advisor | Economics Wonk | Top 5% on TipRanks | Long Signal, Short Noise | Author of The Macro Obsession, a weekly newsletter on current events and trends in finance, tech, and the real economy. My work focuses on my quest to uncover narrative trends before mainstream financial med ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of WPP, OMC, PUBGY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give fina ...

分组1 - NVIDIA Corporation's Q4 '25 earnings showed a remarkable revenue increase of 73% to $68.1 billion [1] - Gross margins expanded by 200 basis points to 75%, indicating no pricing pressure [1] - Operating expenses also increased, although specific figures were not provided [1]

Core Insights - Neurizon Therapeutics has initiated dosing of its lead candidate NUZ-001 in the HEALEY ALS Platform Trial, marking a significant milestone in the development of treatments for amyotrophic lateral sclerosis (ALS) [1][2] Company Overview - Neurizon Therapeutics Limited is a clinical-stage biotechnology company focused on advancing innovative treatments for neurodegenerative diseases, particularly ALS [1] - The company aims to accelerate access to effective ALS treatments while exploring broader applications for NUZ-001 in neurodegenerative disorders [1] Clinical Trial Details - The HEALEY ALS Platform Trial is a multicenter, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial designed to evaluate multiple investigational drugs concurrently [1][2] - Approximately 160 participants with ALS will be enrolled in a 36-week randomized, double-blind, placebo-controlled trial, with a primary objective to assess the efficacy of NUZ-001 compared to placebo [1] - The trial is conducted by the Sean M. Healey & AMG Center for ALS at Mass General Hospital Brigham, in collaboration with the Network of Excellence for ALS (NEALS) [1] Study Design and Objectives - Regimen I of the trial includes a randomized controlled treatment phase followed by an active treatment extension phase, both lasting 36 weeks [1] - Participants will receive either daily NUZ-001 at a dose of 10 mg/kg or a placebo at a 3:1 ratio [1] - Secondary objectives include additional measures of disease progression and safety [1] Infrastructure and Collaboration - The HEALEY ALS Platform Trial leverages shared infrastructure across over 70 clinical sites, enhancing trial efficiency and data generation [1][2] - The trial's design allows for streamlined start-up and enrollment processes, facilitating faster results and ongoing engagement with regulatory authorities, including the FDA [1] Leadership Commentary - The Principal Investigator, Professor Merit Cudkowicz, emphasized the significance of the trial's initiation and the collaboration with Neurizon [1] - Neurizon's Managing Director, Dr. Michael Thurn, highlighted the trial as a registrational study aimed at generating clinical evidence for potential regulatory submissions [1]